webleads-tracker

Pharma Compliance Info EMA Announces Publication of Clinical Trial Reports By Middle of 2016 Open Data

EMA Announces Publication of Clinical Trial Reports By Middle of 2016

The European Medicines Agency (EMA) bases its scientific opinions on the results of clinical trials carried out and submitted by pharmaceutical companies.
On 1 January 2015 a new EMA policy on publication of clinical data entered into force. Under this policy, the Agency proactively publishes the clinical reports submitted as part of marketing-authorisation applications for human medicines. Since 2010 the Agency has been releasing clinical-trial reports on request, under its access-to-documents policy.
The Agency is committed to continuously extending its approach to transparency. A key goal in this process is the publication of clinical-trial data for medicines once the decision-making process on an application for a European Union (EU)-wide marketing authorisation is complete.
The Agency embarked on this process because it believes that the release of data is about establishing trust and confidence in the system, because it will allow the public to better understand the Agency’s decision-making.
In addition, academics and researchers will be able to re-assess data sets. The publication of clinical reports will also help to avoid duplication of clinical trials, foster innovation and encourage development of new medicines.

In October 2014, the Agency published its final policy on publication of clinical data:
The policy entered into force on 1 January 2015. It will apply to clinical reports contained in all marketing-authorisation applications submitted on or after this date. The reports will be released as soon as a decision on the application has been taken. The publication of the first reports is foreseen for mid-2016.

Check Also

Pharma Compliance Info Données anonymisées, données pseudonymisées : de quoi s’agit-il ? Open Data

Données anonymisées, données pseudonymisées : de quoi s’agit-il ?

Collecter des données c’est bien, pouvoir les exploiter c’est mieux, surtout lorsqu’on connait le potentiel …

X